v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
| Column | Value |
|---|---|
| Trial registration number | NCT05273242 |
|
Full text link
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
|
|
First author
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
|
|
Contact
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
prgyawali654@gmail.com |
|
Registration date
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
2022-03-10 |
|
Recruitment status
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Recruiting |
|
Study design
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
RCT |
|
Allocation
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Randomized |
|
Design
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Parallel |
|
Masking
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Open label |
|
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
multi-center |
|
Study aim
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Treatment |
|
Inclusion criteria
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
inclusion criteria: recently hospitalized (or already in hospital) with laboratory-confirmed covid in the view of their doctors, no contra-indication to any potentially relevant study drug. voluntary participation |
|
Exclusion criteria
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
in the view of the randomising doctor, any of the available study drugs are contra-indicated (eg, because of patient characteristics, chronic liver or heart disease, or some concurrent medication). if expected to be transferred within 72 hours |
|
Number of arms
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
4 |
|
Funding
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Nepal Health Research Council |
|
Inclusion age min
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
18 |
|
Inclusion age max
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
100 |
|
Countries
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Nepal |
|
Type of patients
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Moderate/severe disease at enrollment |
|
Severity scale
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
4: Moderate/severe disease at enrollment |
|
Total sample size
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
400 |
|
primary outcome
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Assessment of the Hospital Mortality |
|
Notes
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
None |
|
Phase
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
Phase 4 |
|
Arms
Last imported at : March 12, 2022, midnight Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 121, "treatment_name": "Artesunate", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 650, "treatment_name": "Infliximab", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 631, "treatment_name": "Imatinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |